Personalized mRNA Vaccine Cuts Melanoma Recurrence After Surgery
A large clinical trial found that a personalized mRNA cancer vaccine combined with pembrolizumab (Keytruda) substantially reduced melanoma recurrence in patients who had already undergone tumour surgery — one of the strongest post-surgical outcomes the field has produced.
- Personalized vaccines are synthesized from each patient's tumour genetic profile — no two are identical
- Trial enrolled hundreds of stage 2/3 patients post-resection; recurrence reduction was statistically significant
- mRNA platform enables rapid reformulation if the tumour mutates — a structural advantage over fixed-target approaches